ACN Newswire

Fri Dec 6

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium

Written by ACN Newswire

TOKYO, Dec 5, 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest information on its in-house discovered and developed eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN, "eribulin") will be presented during the 42nd San Antonio Breast Cancer Symposium (SABCS2019). The symposium will be...

ACN Newswire

Eisai to Present New Research on Eribulin (Halaven) at 42nd Annual San Antonio Breast Cancer Symposium

Bonuses for clicks: the Herald Sun model can't be the future of journalism

Not all vaginal implants are a problem and treating them the same puts many women at risk

Tinkering can achieve a lot. Politics isn't broken

We need to plan for life after JobKeeper now. We need to make it portable

Government backs Labor call for Bettina Arndt to lose Order of Australia award

Had pre-eclampsia in pregnancy? These 5 things will lower your risk of heart disease

Have a question about climate? The Conversation and Stuff can help with their New Zealand-based initiative

As the US leaves the UN Human Rights Council, it may leave more damage in its wake

Australia's art institutions don't reflect our diversity: it's time to change that

If you're feeding with formula, here's what you can do to promote your baby's healthy growth

Flights suspended and vital questions remain after second Boeing 737 MAX 8 crash within five months